Lupin sees more US drug approvals after disappointing Q2

Earnings of most Indian generic drugmakers, including Lupin, were hurt in recent quarters by a slowdown in the pace of approvals to launch new drugs, afLer the US Food and Drug Administration overhauled the review process. Lupin shares

Lupin Q2 net dips 35 per cent to Rs 409 crore

NEW DELHI: Drug major Lupin today posted a 35.11 per cent dip in its consolidated net profit at Rs 408.8 crore for the second quarter ended September 30, mainly on account of slowdown in product approvals in the US. This was its worst show in

Lupin, Maruti, Thermax, Axis bank in focus after Q2 nos

Lupin, Maruti, Thermax, Axis bank in focus after Q2 nos. Stocks that are likely to be in focus are: Lupin, Thermax, Axis Bank, Maruti Suzuki India, Tata Communications, Trident, Nucleus Software, Oberoi Realty, Housing Development Finan